This article in RBS Insight shows that "who needs to clear what by whom", and other issues, must not necessarily be clear.
However,
companies using OTC derivatives face a testing time as new rules designed to improve transparency and reduce risk come into focus this yearIMO, it is not only to understand the impact of … on cash flows but how to manage the data and valuation management requirements. It's not just buying a big system ….?